Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in mild to moderate plaque psoriasis
NCT03721172Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Placebo Arm with Apremilast Arm (2 arms). Primary endpoint: Static Physician Global Assessment Response at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03721172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721172.